Description
Andexanet alfa (trade name U.S.: Andexxa, EU: Ondexxya) is a recombinant modified human factor Xa (FXa) protein used for stopping life-threatening or uncontrolled bleeding in adults who are taking a direct factor Xa (FXa) inhibitor or anti-clotting medicines (blood thinners) named apixaban or rivaroxaban.
Recommended Dosage: Dosage of Andexanet alfa should be administered intravenously, through a 0.2 or 0.22-micron in-line polyethersulfone or low protein-binding filter. The recommended dosage of Andexanet alfa is 400 mg administered as an initial intravenous (IV) bolus, with a target rate of 30 mg/min, followed by continuous infusion of 4 mg/min for up to 120 minutes (low dose), or 800 mg administered as an initial intravenous (IV) bolus, with a target rate of 30 mg/min, followed by continuous infusion of 8 mg/min for up to 120 minutes (high dose).
Reviews
There are no reviews yet.